In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Peripartum cardiomyopathy occurs globally and is not a disease of the poor

Pregnancy and Cardiovascular Disease
Heart Failure

Sophia Antipolis, 8 March 2017: Peripartum cardiomyopathy (PPCM) occurs globally and is not a disease of the poor, according to research published today in the European Journal of Heart Failure.1 Cases were reported from many countries for the first time.

“People have always thought PPCM was much more common and severe in Africans and that it was a disease of poverty but our study clearly shows that it’s not,” said lead author Professor Karen Sliwa, director of the Hatter Institute for Cardiovascular Research in Africa, Cape Town, South Africa.

The study was conducted by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Study Group on PPCM under the EURObservational Research Programme (EORP).

PPCM is a structural heart muscle disease that occurs in women either at the end of pregnancy or up to five months after giving birth. Patients were previously healthy and then present with shortness of breath and heart failure.

In about one-third of women with PPCM the heart muscle spontaneously recovers, but about 10% die from the disease and over half have a weakened heart muscle for the rest of their lives. The baby is sometimes born smaller and earlier, and in rare cases it dies.

Research has shown that women with PPCM produce an abnormal breastfeeding hormone that leads to programmed cell death (apoptosis) and damage to the heart muscle.

There is very little known about PPCM and until recently it was assumed that it occurred predominantly in African women. This registry study was conducted to find out whether PPCM occurs in other continents. Specifically, the researchers set out to discover how the disease presents, is diagnosed, and treated in different countries.

The paper published today reports the baseline results of 411 patients from 43 countries representing all continents. Data collected included demographic characteristics, co-morbidities, treatments, type of hospital, and specialisation of the treating physician.

The researchers found cases of PPCM in all 43 countries studied. All women with PPCM presented at the same age, and with the same symptoms and heart size, despite different ethnic backgrounds and huge disparities in socioeconomic factors and access to healthcare.

“Our data shows that PPCM is truly a global disease, and irrespective of where you live, what healthcare system you have, what nutrition you have, and what education you have, you can get this disease,” said Professor Sliwa.

“The disease presented quite uniformly despite occurring globally in different ethnic groups and in very different healthcare systems,” she continued. “This tells us that PPCM is to some extent a biological disease and women might have a genetic predisposition, which is probably a cellular and cardiac signalling abnormality. This is not a disease with marked differences between ethnic groups.”

“We were surprised to see that there is a large percentage of women from the UK, for instance, and from Germany, countries which had not reported many cases so far,” added Professor Sliwa.

One month after diagnosis, 80% of the women with PPCM still had heart failure. About 7% of the women had blood clots – either a stroke, clot to the lung, or clot to the legs. “Despite good access to healthcare and good medical therapy, PPCM remains a very serious disease because many women remain in heart failure or develop blood clots,” said Professor Sliwa.

“PPCM occurs in all health systems and is probably underdiagnosed in many parts of the world,” she continued. “More awareness needs to be created for this disease so that women can be given timely and appropriate treatment.”

The registry aims to recruit 1,000 women with PPCM and will see if there are any differences in six month outcomes between ethnic groups.


Notes to editor

ESC Press Office
Tel: +33 (0) 4 89 87 34 83

SOURCES OF FUNDING: See the paper for funding sources.


References and notes

1Sliwa K, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM). European Journal of Heart Failure. 2017. doi:10.1002/ejhf.780

About the Heart Failure Association

The Heart Failure Association (HFA) is a registered branch of the ESC. Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

About the European Society of Cardiology

The ESC brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.

About the EURObservational Research Programme

The EURObservational Research Programme (EORP) is the large ESC registry programme. EORP aims at providing a better understanding of medical practice in Europe through the collection of observational data and at evaluating the implementation of ESC guidelines.